LEO Pharma Open Innovation

Science

The current assay portfolio consists of the following disease-relevant in vitro bioassays. The selection of assays used in the Open Innovation initiative can vary based on the compounds, scope and status of the assays.

Psoriatic inflammation in human keratinocytes

Primary human keratinocytes are stimulated using a psoriasis-specific cytokine cocktail which induce an inflammatory response measured as an increase in IL-8 secretion. Test compounds are tested for ability to inhibit this inflammatory response. More about psoriatic inflammation in human keratinocytes.

 

Eczematous inflammation in human Keratinocytes

Primary human keratinocyte are stimulated using an eczema-specific cytokine cocktail which induce an inflammatory response measured as an increase in CCL5 secretion. Test compounds are tested for ability to inhibit this inflammatory response. More about eczematous inflammation in human keratinocytes.

  

Human PBMC release of TNF-alpha

This ‘classic’ inflammatory assay utilizes primary human peripheral blood mononulclear cells (PBMCs) activated by LPS. The test compounds are evaluated for their ability to inhibit the LPS-induced TNF-alpha release. A secondary viability readout is also provided. More about human PBMC release of TNF-alpha.

 

IL17 release from human PBMC

Primary human PBMC are stimulated with CD3 and CD28 to release IL-17 and IFN-g. Cell viability is measured in order to determine potential cytotoxicity.
This assay is under development and not currently used routinely.